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Lysophosphatidic acid (LPA) is a serum phospholipid that
evokes growth factor–like responses in many cell types
through the activation of its G protein–coupled receptors.
Although much is known about LPA signaling, it has re-
mained unclear where and how bioactive LPA is produced.
Umezu-Goto et al. (2002, this issue, page 227) have puri-
ﬁed a serum lysophospholipase D that generates LPA from
lysophosphatidylcholine and found it to be identical to auto-
taxin, a cell motility–stimulating ectophosphodiesterase im-
plicated in tumor progression. This result is surprising, as
there was previously no indication that autotaxin could act
as a phospholipase.
 
Lysophospholipids have often been viewed with suspicion
since their accumulation in the plasma membrane leads to
necrosis. One notable exception, however, is lysophosphatidic
acid (LPA;* monoacyl-glycerol-3-phosphate), which has
emerged as an extracellular signaling lipid that evokes
hormone- and growth factor–like responses in almost every
mammalian cell type (Moolenaar, 1999). It does so by acti-
vation of its cognate G protein–coupled receptors (GPCRs),
termed LPA
 
1
 
/Edg2, LPA
 
2
 
/Edg4 and LPA
 
3
 
/Edg7, with
LPA
 
1
 
/Edg2 being the first identified and most widely ex-
pressed subtype (Contos et al., 2000). The cellular responses
to LPA are remarkably diverse, ranging from cell proliferation
and survival to induction of neurite retraction and inhibition
of gap junctional communication (Moolenaar, 1999; Contos
et al., 2000). Although most often associated with proliferative
responses, LPA also stimulates cell motility and migration.
Cell migration is driven by signaling pathways controlled by
Rho GTPases (Nobes and Hall, 1999) and is fundamental
to many normal and pathophysiological processes. Thus,
migration plays a central role not only in embryonic develop-
ment but also in the progression of tumors from a noninvasive
to an invasive and metastatic phenotype. The role of LPA as
a “motility factor” is highlighted by its ability to stimulate
Rho/Rac-dependent invasion of tumor cells across a mono-
layer of normal cells and to promote wound healing both in
vitro and in vivo (Stam et al., 1998; Sturm et al., 1999).
Although much progress has been made in understanding
LPA signaling, the mechanism of LPA production/secretion
has remained unsolved. It has long been known that LPA is
a major constituent of serum and originates from platelet
activation. LPA also accumulates in conditioned media
from cultured cells, whereas its levels are elevated in ascitic
fluids from cancer patients, suggesting a role for LPA in the
spread of interperitoneal malignancies (for references see
Moolenaar, 1999). More than 15 years ago, Tokumura and
coworkers discovered a lysophospholipase D (lysoPLD)
activity in plasma that generates LPA from lysophosphatidyl-
choline (LPC; Tokumura et al., 1999). A bacterial secreted
PLD can generate LPA from preexisting LPC in the outer
membrane leaflet of its target cells (van Dijk et al.,1998),
but unlike plasma lysoPLD, bacterial PLD also attacks di-
acylphospholipids. Plasma lysoPLD plays a key role in the
production of LPA following platelet activation (Sano et al.,
2002), but its molecular identity has never been determined.
A major step forward has now been made by Aoki and
coworkers (Umezu-Goto et al., 2002) who report the pu-
rification of lysoPLD from bovine serum. Surprisingly,
lysoPLD appears to be identical to the “autocrine motility
factor” autotaxin (ATX), a widely expressed ectophoshodi-
esterase that was previously thought to act through nucleotide
signaling (see below). The significance of this finding should
not be underplayed as it not only reveals a novel function for
ATX but also interlinks previously unconnected areas of cell
biology. ATX was originally isolated as a 125-kD glycoprotein
that stimulates tumor cell motility in a pertussis toxin–sensitive
manner (for review see Stracke et al., 1997), whereas more
recent evidence supports an in vivo role for ATX in tumor
progression and metastasis (Nam et al., 2000). In addition,
ATX promotes angiogenesis in vivo and may contribute to
tumor growth by promoting new blood vessel formation
(Nam et al., 2001). Interestingly, expression analysis has
suggested a role for ATX in oligodendrocyte differentiation
and myelination (Fuss et al., 1997), a function also ascribed to
the prototypic LPA receptor LPA
 
1
 
/Edg2 (Contos et al., 2000).
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ATX/lysoPLD belongs to the nucleotide pyrophosphatase
and phosphodiesterase (NPP) family of ectoenzymes, which
to date consists of three members (Goding et al., 1998; Bol-
len et al., 2000; Table I). These enzymes hydrolyze phos-
phodiester and pyrophosphate bonds, typically found in
ATP and ADP, and thereby generate nucleoside 5
 
 
 
-mono-
phosphates. The NPPs are transmembrane proteins with a
very short NH
 
2
 
-terminal region, a single transmembrane do-
main, two cysteine-rich somatomedin B–like domains possi-
bly involved in dimerization, and a large catalytic domain.
Soluble ATX/lysoPLD is derived from the membrane-
bound form by extracellular proteolytic cleavage (Stracke et
al., 1997; Fig. 1).
Until now, there were no indications that ATX could
function as a lysoPLD, since its sequence lacks the conserved
motifs that characterize the PLD superfamily. Instead, ATX
was thought to act by influencing extracellular nucleotide
metabolism and/or recycling. With hindsight, however, this
idea was perhaps not too appealing. Although ATP, ADP,
and adenosine are bona fide GPCR ligands, it is difficult to
envision how altered nucleotide processing in the extracellu-
lar environment could account for the observed biological
effects of ATX. The report by Umezu-Goto et al. (2002)
now provides conclusive evidence that the biological effects
of recombinant ATX/lysoPLD are mediated by newly gener-
ated LPA, negating the need to invoke a role for extracellular
nucleotide metabolism.
The major physiological substrate for ATX/lysoPLD,
LPC, is secreted by the liver and circulates at high concen-
trations in plasma, complexed to albumin and lipoproteins.
Umezu-Goto et al. (2002) detect significant amounts of
LPC and phosphatidylcholine (PC) in serum-free superna-
 
Table I. 
 
Autotaxin/lysoPLD and family members
Enzyme Other names Proposed biological roles Expression 
 
ATX/lysoPLD NPP2, PD-1
 
 
 
Tumor cell motility, 
metastasis
 
a
 
, angiogenesis
 
b
 
, 
myelination
 
c
 
Nearly ubiquitous (not in liver and thymus); 
up-regulated by BMP-2, bFGF
 
b
 
, retinoic acid
 
d
 
, and 
Wnt-1 signaling
 
d
 
; down-regulated by interferon-
 
 
 
PC-1 NPP1 Bone calcification Nearly ubiquitous (not in lung and ovary)
gp130
 
RB13-6
 
NPP3, PD-1
 
 
 
, B10 Glial differentiation, 
cell motility/invasion
 
e
 
Nearly ubiquitous (not in heart, lung and ovary)
For review and primary references see Stracke et al. (1997), Goding et al. (1998), and Bollen et al. (2000). Two putative new members, NPP4 and NPP5
(Bollen et al. 2000), are not included. 
 
a
 
Nam et al. (2000).
 
b
 
Nam et al. (2001).
 
c
 
Fuss et al. (1997).
 
d
 
Tice et al. (2002).
 
e
 
Deissler et al. (1999).
Figure 1. Production of bioactive LPA by auto-
taxin/lysoPLD. ATX/lysoPLD is a type-II transmem-
brane glycoprotein that is proteolytically cleaved, 
as indicated, to yield a soluble exoenzyme. Solu-
ble ATX/lysoPLD hydrolyzes carrier-bound and 
membrane-associated LPC (and other lysophos-
pholipids) to generate LPA. Newly produced LPA 
acts on its own G protein–coupled receptors and 
thereby evokes numerous cellular responses, in-
cluding Ras-mediated cell proliferation and Rho/
Rac-regulated cell migration. Excess LPA is con-
verted into monoacylglycerol (MAG) by mem-
brane-bound lipid phosphatases. See text for fur-
ther details. 
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tants from tumor cells. The source of this “secreted” LPC
and PC is unknown, although it seems likely that both lipids
are constituents of shed microvesicles. This suggests that
ATX/lysoPLD hydrolyzes not only carrier-bound and free
LPC, but also membrane-associated LPC.
The connection that has now been established between a
NPP family member and the production of a bioactive lyso-
phospholipid raises new questions that call for further study.
A compelling question is whether the other NPP family
members, PC-1/NPP1 and gp130
 
RB13–6
 
/NPP3, have a simi-
lar phospholipase function. PC-1/NPP1 plays a role in bone
calcification (Goding et al., 1998), whereas gp130
 
RB13–6
 
/
NPP3 has been implicated in glial differentiation (Deissler
et al. 1999; Table I). Although it is not immediately clear
how ectophospholipase activity could account for these bio-
logical effects, the report by Umezu-Goto et al. (2002) paves
the way toward testing this notion. Other open questions
concern the regulation of ATX/lysoPLD activity and expres-
sion. Is the membrane-bound form ATX/lysoPLD catalyti-
cally active and how is its cleavage regulated? If the soluble
form of ATX/lysoPLD is constitutively active, the question
arises as to how extracellular LPA accumulation is kept in
check. One scenario is that phospholipid ectophosphatases
(Waggoner et al., 1999) cooperate with ATX/lysoPLD to
control the local concentration of receptor-active LPA. Fi-
nally, it is noteworthy that ATX/lysoPLD mRNA is up-reg-
ulated by peptide growth factors, retinoic acid, and Wnt-1
signaling (at least in a mammary epithelial cell line; Tice et
al., 2002; Table I). This suggests unexplored connections
between LPA signaling and other receptor signaling net-
works. Answers to these questions and further insights into
the control of lysophospholipid signaling will undoubtedly
emerge in the not too distant future.
 
Submitted: 20 June 2002
Accepted: 27 June 2002
 
References
 
Bollen, M., R. Gijsbers, H. Ceulemans, W. Stalmans, and C. Stefan. 2000. Nucle-
otide pyrophosphatases/phosphodiesterases on the move
 
.
 
 
 
Crit. Rev. Biochem.
Mol. Biol.
 
 35:393–432.
Contos, J.J., I. Ishii, and J. Chun. 2000. Lysophosphatidic acid receptors. 
 
Mol.
Pharmacol.
 
 58:1188–1196.
Deissler, H., S. Blass-Kampmann, E. Bruyneel, M. Mareel, and M.F. Rajewsky.
1999. Neural cell surface differentiation antigen gp130
 
RB13-6
 
 induces fibro-
blasts and glioma cells to express astroglial proteins and invasive properties.
 
FASEB J.
 
 13:657–666.
van Dijk, M.C., F. Postma, H. Hilkmann, K. Jalink, W.J. van Blitterswijk, and
W.H. Moolenaar. 1998. Exogenous phospholipase D generates lysophos-
phatidic acid and activates Ras, Rho and Ca
 
2
 
 
 
 signaling pathways. 
 
Curr.
Biol.
 
 8:386–392.
Fuss, B., H. Baba, T. Phan, V.K. Tuohy, and W.B. Macklin. 1997. Phosphodi-
esterase I, a novel adhesion molecule and/or cytokine involved in oligoden-
drocyte function. 
 
J. Neurosci.
 
 17:9095–9103.
Goding, J.W., R. Terkeltaub, M. Maurice, P. Deterre, A. Sali, and S.I. Bell. 1998.
Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid
cells: structure and function of the PC-1 family. 
 
Immunol. Rev.
 
 161:11–26.
Moolenaar, W.H. 1999. Bioactive lysophospholipids and their G protein-coupled
receptors. 
 
Exp. Cell Res.
 
 253:230–238.
Nam, S.W., T. Clair, C.K. Campo, H.Y. Lee, L.A. Liotta, and M.L. Stracke. 2000.
Autotaxin (ATX), a potent tumor motogen, augments invasive and meta-
static potential of ras-transformed cells. 
 
Oncogene.
 
 19:241–247.
Nam, S.W., T. Clai, Y.S. Kim, A. McMarlin, E. Schiffmann, L.A. Liotta, and M.L.
Stracke. 2001. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an
angiogenic factor. 
 
Cancer Res.
 
 61:6938–6944.
Nobes, C.D., and A. Hall. 1999. Rho GTPases control polarity, protrusion, and
adhesion during cell movement. 
 
J. Cell Biol.
 
 144:1235–1244.
Sano, T., D.L. Baker, T. Virag, A. Wada, Y. Yatomi, T. Kobayashi, Y. Igarashi,
and G.J. Tigyi. 2002. Multiple mechanisms linked to platelet activation re-
sult in lysophosphatidic acid and sphingosine-1-phosphate generation in
blood. 
 
J. Biol. Chem.
 
 277:21197–21206.
Stam, J.C., F. Michiels, R.A. van der Kammen, W.H. Moolenaar, and J.G. Col-
lard. 1998. Invasion of T-lymphoma cells: cooperation between Rho family
GTPases and lysophospholipid receptor signaling. 
 
EMBO J.
 
 17:4066–4074.
Stracke, M.L., T. Clair, and L.A. Liotta. 1997. Autotaxin, tumor motility-stimulat-
ing exo-phosphodiesterase. 
 
Adv. Enzyme Regul.
 
 37:135–144.
Sturm, A., T. Sudermann, K.M. Schulte, H. Goebell, and A.U. Dignass. 1999.
Modulation of intestinal epithelial wound healing in vitro and in vivo by
lysophosphatidic acid. 
 
Gastroenterology.
 
 117:368–377.
Tice, D.A., W. Szeto, I. Soloviev, B. Rubinfeld, S.E. Fong, D.L. Dugger, J. Winer,
P.M. Williams, D. Wieand, V. Smith, et al. 2002. Synergistic induction of
tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene ex-
pression profiling. 
 
J. Biol. Chem.
 
 277:14329–14335.
Tokumura, A., Y. Nishioka, O. Yoshimoto, J. Shinomiya, and K. Fukuzawa. 1999.
Substrate specificity of lysophospholipase D which produces bioactive lyso-
phosphatidic acids in rat plasma. 
 
Biochim. Biophys. Acta.
 
 1437:235–245.
Umezu-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori,
G.B. Mills, K. Inoue, J. Aoki, and H. Arai. 2002. Autotaxin has lysophos-
pholipase D activity leading to tumor cell growth and motility by lysophos-
phatidic acid production. 
 
J. Cell Biol.
 
 158:227–233.
Waggoner, D.W., J. Xu, I. Singh, R. Jasinska, Q.X. Zhang, and D.N. Brindley.
1999. Structural organization of mammalian lipid phosphate phosphatases:
implications for signal transduction. 
 
Biochim. Biophys. Acta.
 
 1439:299–316.